Get the Stockscreener App
5.16
3.73%
-0.20
After Hours:
5.16
Abeona Therapeutics Inc stock is traded at $5.16, with a volume of 1.40M.
It is down -3.73% in the last 24 hours and down -2.64% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$5.36
Open:
$5.37
24h Volume:
1.40M
Relative Volume:
0.81
Market Cap:
$279.63M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.00
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-1.71%
1M Performance:
-2.64%
6M Performance:
-23.10%
1Y Performance:
-1.71%
1-Day Range:
$5.14
$5.37
1-Week Range:
$5.045
$5.405
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.16 | 290.47M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Abeona Therapeutics CEO Seshadri Vishwas sells $372k in shares By Investing.com - Investing.com India
Abeona Therapeutics CFO Vazzano sells $99k in shares By Investing.com - Investing.com Australia
Abeona Therapeutics (NASDAQ:ABEO) CEO Sells $372,204.56 in Stock - MarketBeat
Joseph Walter Vazzano Sells 18,666 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock - MarketBeat
Abeona Therapeutics CEO Seshadri Vishwas sells $372k in shares - Investing.com
O’Malley, Abeona Therapeutics SVP, sells $72k in stock By Investing.com - Investing.com South Africa
O’Malley, Abeona Therapeutics SVP, sells $72k in stock - Investing.com
Insider Sell: Mark Alvino Sells 13,500 Shares of Abeona Therapeu - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) Director Mark Alvino Sells 13,500 Shares - MarketBeat
Breakouts Watch: Is Abeona Therapeutics Inc stock forming a cup and handleDay Trade & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Jobs Data: Is OneWater Marine Inc on track to beat earningsMarket Weekly Review & Long Hold Capital Preservation Plans - baoquankhu1.vn
How (ABEO) Movements Inform Risk Allocation Models - Stock Traders Daily
Published on: 2026-01-17 07:33:28 - baoquankhu1.vn
Abeona Therapeutics (NASDAQ:ABEO) Share Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Abeona Therapeutics stock By Investing.com - Investing.com Canada
Big Picture: Is Abeona Therapeutics Inc in a bullish channelQuarterly Earnings Report & Weekly Breakout Watchlists - baoquankhu1.vn
Is Abeona Therapeutics Inc. (PCJ) stock inflation resilient2025 Bull vs Bear & Daily Technical Stock Forecast Reports - Улправда
Why Abeona Therapeutics Inc. stock remains a top recommendationJuly 2025 Chart Watch & Proven Capital Preservation Methods - Улправда
How Abeona Therapeutics Inc. stock compares to industry benchmarksWeekly Trend Recap & Weekly High Potential Stock Alerts - Улправда
Will Abeona Therapeutics Inc. (PCJ) stock draw ESG focused funds2026 world cup usa national team round of 32 defensive leaders counter attacking knockout prediction guide - Улправда
Trading Systems Reacting to (ABEO) Volatility - Stock Traders Daily
3 Insider-Owned Growth Stocks For Your Watchlist - simplywall.st
Abeona Therapeutics announces employee inducement grants - MSN
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Abeona Therapeutics (ABEO) Issues Equity Awards to New Staff - GuruFocus
Abeona Therapeutics® announces new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New hires at Abeona Therapeutics get stock that vests over 3 years - Stock Titan
Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Vishwas Seshadri Sells 25,000 Shares of Abeona The - GuruFocus
Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 25,000 Shares - MarketBeat
Avoiding Lag: Real-Time Signals in (ABEO) Movement - Stock Traders Daily
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a Potential 281% Upside in Gene Therapy - DirectorsTalk Interviews
Is Abeona Therapeutics Inc. stock dividend yield sustainableEarnings Growth Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Would You Still Hold Abeona Therapeutics Stock If It Fell 30%? - Trefis
Short Covering: Why institutional investors increase stakes in Abeona Therapeutics Inc. (PCJ) stockM&A Rumor & Weekly High Momentum Picks - Улправда
How Abeona Therapeutics Inc. stock performs in stagflation2025 Geopolitical Influence & Weekly Watchlist for Hot Stocks - Улправда
How Abeona Therapeutics Inc. stock performs in high volatility markets2025 Valuation Update & Precise Trade Entry Recommendations - Улправда
Can Abeona Therapeutics Inc. stock reach $100 price targetPortfolio Growth Summary & Low Risk High Win Rate Picks - ulpravda.ru
How Abeona Therapeutics Inc. stock reacts to global recession fearsTrade Entry Report & Real-Time Price Movement Reports - ulpravda.ru
Abeona Therapeutics appoints Mohamad Tabrizi as chief business officer By Investing.com - Investing.com Nigeria
Abeona Therapeutics appoints Mohamad Tabrizi as chief business officer - Investing.com
Abeona Therapeutics names Mohamad Tabrizi as chief business officer - marketscreener.com
Abeona Therapeutics Appoints Mohamad Tabrizi as Senior Vice President, Chief Business Officer - Quiver Quantitative
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer - marketscreener.com
(ABEO) Risk Channels and Responsive Allocation - Stock Traders Daily
Quarterly Earnings: Will Abeona Therapeutics Inc stock benefit from M A activityJuly 2025 Sector Moves & Safe Capital Growth Tips - moha.gov.vn
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):